JP2019531742A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531742A5 JP2019531742A5 JP2019520685A JP2019520685A JP2019531742A5 JP 2019531742 A5 JP2019531742 A5 JP 2019531742A5 JP 2019520685 A JP2019520685 A JP 2019520685A JP 2019520685 A JP2019520685 A JP 2019520685A JP 2019531742 A5 JP2019531742 A5 JP 2019531742A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- antigen
- protein
- tcr
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410187P | 2016-10-19 | 2016-10-19 | |
| US62/410,187 | 2016-10-19 | ||
| DKPA201770240 | 2017-03-31 | ||
| DKPA201770240 | 2017-03-31 | ||
| PCT/EP2017/076800 WO2018073393A2 (en) | 2016-10-19 | 2017-10-19 | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531742A JP2019531742A (ja) | 2019-11-07 |
| JP2019531742A5 true JP2019531742A5 (enExample) | 2023-01-25 |
| JP7236380B2 JP7236380B2 (ja) | 2023-03-09 |
Family
ID=60268352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520685A Active JP7236380B2 (ja) | 2016-10-19 | 2017-10-19 | 治療に適したｔａｌエフェクターヌクレアーゼ（ｔａｌｅｎ）改変同種異系細胞 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12655451B2 (enExample) |
| EP (1) | EP3529265A2 (enExample) |
| JP (1) | JP7236380B2 (enExample) |
| AU (1) | AU2017347685B2 (enExample) |
| CA (1) | CA3041039A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191257A1 (ru) | 2018-11-07 | 2021-12-06 | Криспр Терапьютикс Аг | Противораковая терапия на основе иммуноцитов, связывающих liv1 |
| US20230332104A1 (en) * | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| CN117129690B (zh) * | 2023-09-26 | 2025-06-06 | 杭州师范大学 | Grhl1在her2-乳腺癌诊断及预后评估中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201806573TA (en) * | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| JP6608807B2 (ja) * | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| RU2752933C2 (ru) * | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| US20190024065A1 (en) * | 2015-02-06 | 2019-01-24 | Cellectis | Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles |
| BR112017020750A2 (en) * | 2015-03-27 | 2018-06-26 | President And Fellows Of Harvard College | modified t-cells and methods of producing and using them |
| ES2803728T3 (es) * | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| SG11201808457PA (en) * | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
-
2017
- 2017-10-19 JP JP2019520685A patent/JP7236380B2/ja active Active
- 2017-10-19 US US16/340,412 patent/US12655451B2/en active Active
- 2017-10-19 EP EP17794690.2A patent/EP3529265A2/en active Pending
- 2017-10-19 CA CA3041039A patent/CA3041039A1/en active Pending
- 2017-10-19 AU AU2017347685A patent/AU2017347685B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273201B1 (en) | Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy | |
| JP2023518049A5 (enExample) | ||
| US12410248B2 (en) | Chimeric antigen receptor and its use | |
| JP2025037871A5 (enExample) | ||
| IL321733A (en) | Compositions and methods for selective degradation of proteins | |
| JP2024518011A5 (enExample) | ||
| JP2021500861A5 (enExample) | ||
| HRP20202062T1 (hr) | Puferi za stabilizaciju lentivirusnih pripravaka | |
| AU2017233072B2 (en) | Multimodal vector for dendritic cell infection | |
| FI3380620T3 (fi) | Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja | |
| JP2020517263A5 (enExample) | ||
| IL297547A (en) | Therapeutic interventional particles for the corona virus | |
| IL297514A (en) | Vectors and methods for in vivo transduction | |
| CN110511912A (zh) | 免疫细胞的功能调节 | |
| JP2024510900A5 (enExample) | ||
| KR20230150834A (ko) | Ap-1 전사 인자를 인코딩하는 코돈-최적화된 뉴클레오티드 서열 | |
| Zhou et al. | A novel transgenic mouse model for immunological evaluation of carcinoembryonic antigen–based DNA minigene vaccines | |
| JP2022516710A5 (enExample) | ||
| JP7236380B2 (ja) | 治療に適したｔａｌエフェクターヌクレアーゼ（ｔａｌｅｎ）改変同種異系細胞 | |
| EP4486373A1 (en) | Allogeneic therapeutic cells | |
| HK40115321A (en) | Allogeneic therapeutic cells | |
| JP2026514801A (ja) | 免疫拒絶のリスクが低減された同種異系治療用細胞 | |
| Zhu et al. | HLA-A0201 positive pancreatic cell lines: new findings and discrepancies | |
| WO2026069206A1 (en) | Hypoimmunogenic modified gamma delta t cells | |
| EA050762B1 (ru) | Аллогенные терапевтические клетки |